Alkermes’ depression treatment fails to get FDA panel backing
By Saumya Joseph (Reuters) – An advisory panel to the U.S. Food and Drug Administration on Thursday voted against approving Alkermes Plc’s treatment for depression in patients with an inadequate response to standard...
Read More